Wilsonian crisis (hemolytic crisis and acute liver failure [ALF] in Wilson’s disease) is fatal and almost all patients ultimately need a timely liver transplantation to save their lives. How to safely pass the critical period to liver transplantation is still a big challenge to doctors especially to pediatricians facing more difficult situations in blood purification. Here, we report about a 7-year-old child (weight 21 kg) presenting with severe hemolysis and impending ALF that made a rapid recovery with prompt initiation of plasmapheresis combined with continuous plasma filtration adsorption (CPFA) and chelation therapy. Rapidly efficient removal of copper, bilirubin, and albumin-binding toxins by hybrid blood purification alleviated hemolysis and liver injury and successfully bridged the patient over the critical period to late liver transplantation. Moreover, a review of the literature was performed examining the use of plasmapheresis, molecular adsorbent recirculation system, single-pass albumin dialysis, and continuous veno-venous hemodiafiltration in Wilson disease. The experience of our case points to that plasmapheresis combined with CPFA treatment can improve clinical symptoms and bridge children over through Wilsonian crisis to late live transplantation, and CPFA treatment is feasible and safe in children weighing more than 20 kg.

Keywords:
Wilsonian crisis, Hemolytic crisis, Acute liver failure, Plasmapheresis, Continuous plasma filtration adsorption
1.
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML: Wilson’s disease. Lancet 2007; 369: 397–408.
2.
Bandmann O, Weiss KH, Kaler SG: Wilson’s disease and other neurological copper disorders. Lancet Neurol 2015; 14: 103–113.
3.
European Association for Study of Liver: EASL clinical practice guidelines: -Wilson’s disease. J Hepatol 2012; 56: 671–685.
4.
Weiss KH, Schäfer M, Gotthardt DN, Angerer A, Mogler C, Schirmacher P, Schemmer P, Stremmel W, Sauer P: Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 2013; 27: 914–922.
5.
Eisenbach C, Sieg O, Stremmel W, Encke J, Merle U: Diagnostic criteria for acute liver failure due to Wilson disease. World J Gastroenterol 2007; 13: 1711–1714.
6.
Reynolds HV, Talekar CR, Bellapart J, Leggett BA, Boots RJ: Copper removal strategies for Wilson’s disease crisis in the ICU. Anaesth Intensive Care 2014; 42: 253–257.
7.
Camussi G, Ronco C, Montrucchio G, Piccoli G: Role of soluble mediators in sepsis and renal failure. Kidney Int Suppl 1998; 66:S38–S42.
8.
Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, De Nitti C, Inguaggiato P, Tetta C: Adsorption in sepsis. Kidney Int Suppl 2000; 76:S148–S155.
9.
Bellomo R, Ronco C: Blood purification in the intensive care unit: evolving concepts. World J Surg 2001; 25: 677–683.
10.
Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, Pickkers P, Cantaluppi V, Turani F: Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015; 19: 146.
11.
Ricci Z, Ronco C, Bachetoni A, D’amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
12.
Bellomo R, Ronco C: Acute renal failure in the intensive care unit: adequacy of dialysis and the case for continuous therapies. Nephrol Dial Transplant 1996; 11: 424–428.
13.
Levin A, Warnock DG, Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C; Acute Kidney Injury Network Working Group: Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 2007; 50: 1–4.
14.
Morgan SM, Zantek ND: Therapeutic plasma exchange for fulminant hepatic failure secondary to Wilson’s disease. J Clin Apher 2012; 27: 282–286.
15.
Kido J, Matsumoto S, Momosaki K, Sakamoto R, Mitsubuchi H, Inomata Y, Endo F, Nakamura K: Plasma exchange and chelator therapy rescues acute liver failure in Wilson disease without liver transplantation. Hepatol Res 2017; 47: 359–363.
16.
Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH: Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. J Clin Apher 2013; 28: 145–284.
17.
Schaefer B, Schmitt CP: The role of molecular adsorbent recirculating system dialysis for extracorporeal liver support in children. Pediatr Nephrol 2013; 28: 1763–1769.
18.
Asfaha S, Almansori M, Qarni U, Gutfreund KS: Plasmapheresis for hemolytic crisis and impending acute liver failure in Wilson disease. J Clin Apher 2007; 22: 295–298.
19.
Humphreys GD, Kent P, Kevy SV, Wayne AS: Intensive plasma exchange in a patient with Wilson’s disease (Abstract). J Clin Apheresis 1992; 7: 31–32.
20.
Kiss JE, Berman D, Van Thiel D: Effective removal of copper by plasma exchange in fulminant Wilson’s disease. Transfusion 1998; 38: 327–331.
21.
Matsumura A, Hiraishi H, Terano A: Plasma exchange for hemolytic crisis in Wilson disease. Ann Intern Med 1999; 131: 866.
22.
Nagata Y, Uto H, Hasuike S, Ido A, Hayashi K, Eto T, Hamakawa T, Tanaka K, Tsubouchi H: Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson’s disease. Intern Med 2003; 42: 967–970.
23.
Reynolds HV, Talekar CR, Bellapart JB, Leggett BA, Boots RJ: Therapeutic plasma exchange as de-coppering technique in intensive care for an adult in a Wilson’s crisis. Anaesth Intensive Care 2013; 41: 811–812.
24.
Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30: 1250–1255.
25.
Berlot G, Bianco N, Tomasini A, Vassallo MC, Bianco F: Changes in microvascular blood flow during coupled plasma filtration and adsorption. Anaesth Intensive Care 2011; 39: 687–689.
26.
Mao HJ, Yu S, Yu XB, Zhang B, Zhang L, Xu XR, Wang XY, Xing CY: Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Int J Artif Organs 2009; 32: 31–38.
27.
Caroleo S, Rubino AS, Tropea F, Bruno O, Vuoto D, Amantea B, Renzulli A: Coupled plasma filtration adsorption reduces serum bilirubine in a case of acute hypoxic hepatitis secondary to cardiogenic shock. Int J Artif Organs 2010; 33: 749–752.
28.
Maggi U, Nita G, Gatti S, Antonelli B, Paolo R, Como G, Messa P, Rossi G: Hyperbilirubinemia after liver transplantation: the role of coupled plasma filtration adsorption. Transplant Proc 2013; 45: 2715–2717.
29.
Aron J, Agarwal B, Davenport A: Extracorporeal support for patients with acute and acute on chronic liver failure. Expert Rev Med Devices 2016; 13: 367–380.
30.
Chiu A, Tsoi NS, Fan ST: Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease. Liver Transpl 2008; 14: 1512–1516.
31.
Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, Williams R, Jalan R: Albumin dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson’s disease. Liver Transpl 2002; 8: 962–967.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.